Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fentanyl + dexmedetomidine is a pharmacological combination used for anesthesia and analgesia. Fentanyl is a potent synthetic opioid that acts as a mu-opioid receptor agonist, providing rapid-onset pain relief. Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist that provides sedation, anxiolysis, and supplemental analgesia with minimal respiratory depression. In a clinical trial conducted by the University of Saskatchewan, this combination was evaluated as a standard-of-care control regimen in children with sleep-disordered breathing or obstructive sleep apnea undergoing tonsillectomy to compare its effects on postoperative respiratory depression against an opioid-free anesthetic protocol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fentanyl + dexmedetomidine (University of Saskatchewan).